Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 373

1.
2.

Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.

de Haan A, Haijema BJ, Voorn P, Meijerhof T, van Roosmalen ML, Leenhouts K.

Vaccine. 2012 Jul 6;30(32):4884-91. doi: 10.1016/j.vaccine.2012.04.032. Epub 2012 Apr 23.

PMID:
22537989
3.

Influenza antigen-sparing by immune stimulation with Gram-positive enhancer matrix (GEM) particles.

Saluja V, Visser MR, Ter Veer W, van Roosmalen ML, Leenhouts K, Hinrichs WL, Huckriede A, Frijlink HW.

Vaccine. 2010 Nov 23;28(50):7963-9. doi: 10.1016/j.vaccine.2010.09.066. Epub 2010 Oct 12.

PMID:
20946860
4.

Antibody contributes to heterosubtypic protection against influenza A-induced tachypnea in cotton rats.

Straight TM, Ottolini MG, Prince GA, Eichelberger MC.

Virol J. 2008 Mar 20;5:44. doi: 10.1186/1743-422X-5-44.

5.

Heterosubtypic cross-protection induced by whole inactivated influenza virus vaccine in mice: influence of the route of vaccine administration.

Budimir N, de Haan A, Meijerhof T, Gostick E, Price DA, Huckriede A, Wilschut J.

Influenza Other Respir Viruses. 2013 Nov;7(6):1202-9. doi: 10.1111/irv.12142. Epub 2013 Sep 16.

6.

Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.

Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V, Massare M, Pushko P, Mytle N, Rowe T, Smith G, Ross TM.

Vaccine. 2007 May 10;25(19):3871-8. Epub 2007 Feb 15.

PMID:
17337102
7.

A DNA vaccine-encoded nucleoprotein of influenza virus fails to induce cellular immune responses in a diabetic mouse model.

Jamali A, Sabahi F, Bamdad T, Hashemi H, Mahboudi F, Kheiri MT.

Clin Vaccine Immunol. 2010 Apr;17(4):683-7. doi: 10.1128/CVI.00445-09. Epub 2010 Feb 17.

8.

Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza vaccines in mice.

Baz M, Samant M, Zekki H, Tribout-Jover P, Plante M, Lanteigne AM, Hamelin ME, Mallett C, Papadopoulou B, Boivin G.

Clin Vaccine Immunol. 2012 Feb;19(2):209-18. doi: 10.1128/CVI.05441-11. Epub 2011 Dec 21.

9.

Induction of heterosubtypic immunity to influenza virus by intranasal immunization.

Quan FS, Compans RW, Nguyen HH, Kang SM.

J Virol. 2008 Feb;82(3):1350-9. Epub 2007 Nov 21.

10.

A pandemic influenza H1N1 live vaccine based on modified vaccinia Ankara is highly immunogenic and protects mice in active and passive immunizations.

Hessel A, Schwendinger M, Fritz D, Coulibaly S, Holzer GW, Sabarth N, Kistner O, Wodal W, Kerschbaum A, Savidis-Dacho H, Crowe BA, Kreil TR, Barrett PN, Falkner FG.

PLoS One. 2010 Aug 16;5(8):e12217. doi: 10.1371/journal.pone.0012217.

11.

Intramuscular immunization with a vesicular stomatitis virus recombinant expressing the influenza hemagglutinin provides post-exposure protection against lethal influenza challenge.

Barefoot BE, Athearn K, Sample CJ, Ramsburg EA.

Vaccine. 2009 Dec 10;28(1):79-89. doi: 10.1016/j.vaccine.2009.09.112. Epub 2009 Oct 9.

13.

Cross-protective immunity against influenza A/H1N1 virus challenge in mice immunized with recombinant vaccine expressing HA gene of influenza A/H5N1 virus.

Yang S, Niu S, Guo Z, Yuan Y, Xue K, Liu S, Jin H.

Virol J. 2013 Sep 22;10:291. doi: 10.1186/1743-422X-10-291.

14.

Vaccination with NS1-truncated H3N2 swine influenza virus primes T cells and confers cross-protection against an H1N1 heterosubtypic challenge in pigs.

Kappes MA, Sandbulte MR, Platt R, Wang C, Lager KM, Henningson JN, Lorusso A, Vincent AL, Loving CL, Roth JA, Kehrli ME Jr.

Vaccine. 2012 Jan 5;30(2):280-8. doi: 10.1016/j.vaccine.2011.10.098. Epub 2011 Nov 7.

PMID:
22067263
15.

Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers.

Stephenson I, Zambon MC, Rudin A, Colegate A, Podda A, Bugarini R, Del Giudice G, Minutello A, Bonnington S, Holmgren J, Mills KH, Nicholson KG.

J Virol. 2006 May;80(10):4962-70.

16.

[Chitosan as an adjuvant for parenteral inactivated influenza vaccines].

Gendon IuZ, Markushin SG, Krivtsov GG, Akopova II.

Vopr Virusol. 2008 Sep-Oct;53(5):14-9. Russian.

PMID:
19069787
17.

Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in mice.

Huang B, Wang W, Li R, Wang X, Jiang T, Qi X, Gao Y, Tan W, Ruan L.

Virol J. 2012 Dec 29;9:322. doi: 10.1186/1743-422X-9-322.

18.

Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses.

Altstein AD, Gitelman AK, Smirnov YA, Piskareva LM, Zakharova LG, Pashvykina GV, Shmarov MM, Zhirnov OP, Varich NP, Ilyinskii PO, Shneider AM.

Arch Virol. 2006 May;151(5):921-31. Epub 2005 Nov 15.

PMID:
16292596
19.

Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice.

Luo M, Tao P, Li J, Zhou S, Guo D, Pan Z.

J Virol Methods. 2008 Dec;154(1-2):121-7. doi: 10.1016/j.jviromet.2008.08.011. Epub 2008 Sep 27.

PMID:
18789973
20.
Items per page

Supplemental Content

Write to the Help Desk